Clinical evidence points to a role for angiotensin II (Ang II) in the post-infarction remodelling of cardiac hypertrophy. The present study was designed to investigate the remodelling process in an animal model of myocardial infarction (MI) using the following criteria: 1) histological studies to examine the re-vascularisation process and collagen deposition in different regions of the myocardium; 2) histological evidence to investigate the cell type distribution using cell-specific markers; 3) histological and Western blot analysis to localise Ang II receptor subtypes (AT 1 -receptor and AT 2 -receptor) and to study their regulation; 4) kinetics of the binding of Ang II to its receptors in a heart perfusion model; and 5) to assess the effect of the Ang II antagonist (losartan) on these parameters.
Introduction
The renin-angiotensin-aldosterone system (RAAS), previously thought to be present only in the systemic circulation, has also been demonstrated in various tissues of the body. [1] [2] [3] In the heart, angiotensin II (Ang II) elicits its pharmacodynamic effects predominantly by binding with its specific type 1 receptor (AT 1 -receptor). [4] [5] [6] [7] The binding of Ang II to the AT 1 -receptor produces a cascade of intracellular events which are the basis for its physiological responses.These range from positive inotropic and arterial vasoconstrictor effects, to positive mitogenic and growth factor effects. 6 The physiological responses mediated by Ang II type 2 receptor (AT 2 -receptor) activation seem to antagonise those of AT 1 -receptor activation. The growth of cardiomyocytes due to cardiac autocrine/ paracrine release of Ang II is currently thought to be mediated through the AT 1 -receptor rather than through AT 2 -receptor binding. [7] [8] [9] Myocardial infarction (MI) has been shown to increase the production of Ang II, 10 and to induce the upregulation of AT 1 -receptor and AT 2 -receptor subtypes. 11 These events could occur as a sequel to ischaemic insult followed by myocardial stress and impairment of myocardial function, necessitating the mobilisation of different compensatory mechanisms, thus causing remodelling at the cardiomyocyte, vasculature, and extracellular matrix (ECM) levels. [12] [13] [14] [15] Extracellular matrix proteins play a vital role in the regulation of myocardial and vascular structure, since collagen fibres maintain myocyte alignment (myocardial structure) and even distribution of force throughout the myocardium during the cardiac cycle. 16, 17 Furthermore, the ECM directly affects the myofibres through its interaction with integrin. 16 There is increasing evidence implicating integrins in the signalling pathways into and out of myocytes and fibroblasts. 17, 18 Stress, applied to the myocardium and the ongoing remodelling process, increases the production of Ang II to mediate these changes and affects both the expression of AT 1 -receptor and AT 2 -receptor, as well as their binding capacity. Furthermore, lowflow regional ischaemia and reperfusion causes non-elastic deformity of the myocardium, which is reflected by increases in minimally-loaded myocardial dimensions. 19 The objectives of this study were to assess the cardiac remodelling process in a rat model of acute MI, in terms of fibroblast proliferation, collagen deposition, revascularisation and distribution of AT 1 -receptor and AT 2 -receptor, and to evaluate changes in the binding parameters of Ang II to these receptors on heart vascular endothelial cells and cardiomyocytes after losartan treatment.
Model and theory
The micro-anatomical structure of the layers that separate the capillary lumen from the cardiac myocytes presents a suitable model for transcellular transport and cell surface binding of biologically active solutes. 20 The rate limiting steps for binding and transport of macromolecules such as Ang II, involve cell layer permeation via receptormediated endocytosis (internalisation), paracellular diffusion and/or transport across endothelial plasma membranes.The barriers that such macromolecules encounter before reaching the plasmalemma of the cardiac myocyte can be presented as follows ( Figure 1 ): (1) the adluminal plasma membrane of the endothelial cell (≈ 10 nm), (2) the thinnest endothelial cytoplasm (≈ 500-1000 nm), (3) the abluminal plasma membrane of the endothelial cell (≈ 10 nm), (4) the basal lamina of the endothelial cell and that of the cardiac myocyte, plus a minimal extracellular space (≈ 1000 nm), and (5) the plasma membrane of the cardiac myocyte (≈ 10 nm). The diameter of the capillary is normally about 6 µm and the junctions between the microvascular endothelial cells may permit the passage of molecules up to 10 nm in diameter. 21 In order to simplify the flow-limited binding profile of Ang II, the physical model shown in Figure 2 illustrates the processes involved in ligand binding to the plasma membranes of a microvascular endothelial cell (given by rate constant k n and k -n ) and to the plasma membrane of a cardiac myocyte, as given by similar rate constants. The model illustrates perfusate flow with velocity W, enfolded by a microvascular space containing, on its endothelial surface,Ang II receptors, and beyond that exposes the subendothelial intercellular space which bathes cardiac myocyte membrane surfaces, also containing Ang II receptors. The microvascular endothelial cells can be removed by detergent treatment (see under Materials and methods), thus exposing the perfusates directly to the plasma membrane of the cardiac myocyte.
In any of the two experimental situations (before and after treatment with detergent), a conservation equation of the physical model can be proposed:
whereby v(x,t) is the concentration of tracer peptide in interstitial space assumed then to be equal to u(x,t); u(x,t) is the concentration of tracer peptide at the same point along the length x at time t; A is the volume per unit length (L) of the capillary, basal laminae and interstitial spaces; W is the perfusate flow velocity; B is the volume per unit length of basal laminae and interstitial spaces; C is the surface area per unit length of cellular surfaces; and s(x,t) is the cellular surface concentration of receptors along the length x at time t.
At flow-limited binding of the ligand with its receptor, while utilising a Dirac delta function or impulse function and a first order Bessell function whereby F S = A.W and q o = input rate per unit of time. In the curve fit of the data one determines a(1), a(2) and a(3) directly. From a(1) one obtains k -n ; from a(2) and knowing k -n and one may determine k n ; and from a(3) with knowledge of , one can also determine k n and k d = k -n /k n . 20
Materials and methods

Surgical procedures
All experiments were conducted with the approval of the Institutional Review Board/Animal House Committee of the American University of Beirut and in accordance with the AAALAC guidelines.
MI was surgically induced in female Sprague-Dawley rats (250-300 g) by ligation of the left anterior descending coronary artery. Rats were anaesthetised by intra-peritoneal (ip) injection of largactil (8 mg/kg bw) followed 10 minutes later by ketamine (45 mg/kg bw). After anaesthesia, animals were fixed on a heating pad (37°C), and endotracheal intubation was performed and a tube connected to a positive pressure respirator was introduced. After establishing positive pressure respiration, the thorax was opened at the fourth intercostal space, and ligation of the left anterior descending coronary artery was performed, using 6-0 silk suture.The thorax was then closed in layers, the endotracheal tube removed and the rats returned to normal respiration; the tracheal opening was closed and the rats were released into the cages, fed ad libitum and divided into four groups; Group I, sham-operated (all steps similar to that of inducing MI but without tightening the coronary artery suture), losartan-non-treated rats; Group II, sham-operated, losartan-treated rats; Group III, MIoperated, losartan-non-treated rats; and Group IV, MI-operated, losartan-treated rats. During perfusion, each group was divided into two subgroups, one subgroup perfused simply with buffer, and the other perfused with 20 mmoL/L of 3-[(3cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS; Sigma Chemical Company, St. Louis, MO) to remove the capillary endothelial lining. Losartan (COZAAR, 50 mg tablets, Merck, Sharp & Dohme, Haarlem, Netherlands) treatment (3 mg/kg bw, bid) was given by oral gavage for a period of one month.After this, the rats were weighed, then anaesthetised (pentobarbital 50 mg/kg bw ip); each rat was fixed to a heating pad and positive pressure endotracheal intubation was performed. The skin was then incised from the mid-gastric region longitudinally to the sternal notch.The abdominal muscular layer was longitudinally cut to the xyphoid; from that point, the thoracic cavity was exposed by cutting through the midclavicular lines on each side of the thorax.Thus, the whole thoracic cavity was fully exposed to perform heart perfusion while the rat was still under positive pressure respiration.
Rat heart perfusion
The right and left superior venae cavae, as well as the inferior vena cava, were isolated and ties placed around them. A polyethylene catheter was introduced into the lumen of the aorta from cephalad to caudad to sit with its tip in the region of the coronary artery openings, without damaging the aortic valve.This site was used as the inlet of the perfusate that was collected from the right atrium at the site of the coronary sinus via another catheter, and both catheters were firmly anchored with sutures. Concomitantly, the distal descending aorta and all the venae cavae were ligated.The dissected part of the animal and the exposed heart, were soaked with saline at 37°C throughout the experiment.
All perfusion experiments were done as previously reported. 20 First, the heart was cleared of blood by perfusing for 5 minutes with heparinised Ringer-Lock buffer containing 20 meq/L K + , oxygenated with 95% O 2 , 5% CO 2 at 37°C, using an infusion pump. The effluent perfusate was discarded. Secondly,the heart was perfused for 15 minutes with buffer to clear it of heparin. Finally, perfusion of a similar buffer containing ≈1.26±0.10 nM [tyrosyl-3,5 3 H] angiotensin II (5-L-isoleucine) (specific activity, 36.0 Ci/mmol; Amersham International plc., Buckinghamshire,U.K.) was maintained at a rate of 1 mL/minute and the effluent collected at the same rate during specified time intervals for 40 minutes.At the end of every collection, a 0.5 mL sample of perfusate was assayed for radioactivity in a liquid scintillation spectrometer. For the CHAPS perfused groups, all the steps were the same as above, except that before the second step, perfusion with buffer containing CHAPS for a period of 1 minute was performed.
The heart was then excised and separated into right and left ventricles, that were individually weighed.The area of the infarcted region in the left ventricle was then measured by planimetry.A transparent network of specific dimensions was used whereby the area of the infarcted region could be calculated with respect to the total area of the left ventricle. The left ventricle was then divided into two parts. One part, containing both the infarct and the non-infarct regions, was fixed with 4% formaldehyde, while the other, non-infarct, part was homogenised in RIPA buffer containing orthovanedate and protease inhibitor cocktail (Boehringer Mannheim, Germany). The homogenate was centrifuged, the supernatant mixed with sample buffer and stored in aliquots at -20°C for Western blotting analysis.
Tissue preparation for histological studies
Heart tissue was fixed in freshly prepared 4% formaldehyde in phosphate-buffered saline (PBS), imbedded in paraffin and serially sectioned through the left ventricular infarcted and non-
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(Including other peptidergic systems) 
Results
Alterations induced by myocardial infarction
Scar formation and revascularisation MI (in excess of 30% of total heart area as assessed by planometry) caused severe ischaemia and irreversible damage to the region of the heart perfused by the occluded artery.This ischaemia led not only to cell necrosis and formation of a fibrotic scar tissue in the affected region, but also to hypoxia- induced stress throughout the myocardium, owing to the extra compensatory work demanded from the viable myocytes. A representative haematoxylin and eosin histologic section of infarcted rat myocardium is presented in Figure 3a . In this figure, both normal myocardial tissue and scar tissue are evident. The scar tissue depicted a major vessel that appeared non-functional due to endothelial lining sloughing. The hypoxia stress also induced angiogenesis and formation of new vessels, as confirmed by α-actin staining of smooth muscle cells surrounding blood vessels. An increase in the vascularisation and myofibroblast cell population was evident in the scar tissue, while in the surrounding myocardium, an increased number of vessel profiles is observed (Figure 3 , b, c and d). Table 1 
Cardiac hypertrophy
Distribution of AT-receptors
Immunofluorescence labelling of AT 1 -receptor was performed in different regions of the heart. In non-infarcted myocardial tissue sections, AT 1receptor specific antibodies revealed a distinct distribution pattern of these receptors on cells of the extracellular matrix (ECM) and at the smooth muscle cell (SMC) levels (Figure 4b ). AT 1 -receptor appears to be diffusely distributed in the vascular tissue, myocytes and fibroblasts and in the vessels, AT 1 -receptor appears to be specifically localised in the SMCs (Figure 4b ). Its localisation to myocytes and fibroblasts is evident even after induction of MI (Figure 4d ). The distribution of AT 2 -receptor in the heart tissue is represented in Figure 5 . AT 2 -receptor is Figure 4 Indirect immunoflourescence (FITC-labelled) micrographs (40x) of histological sections of non-infarct rat myocardium area. A. shows a control section where the primary anti-AT 1 -receptor is not used. B. specific staining for AT 1 -receptor in smooth muscle cells and extracellular matrix. Histological sections (20x) of non-infarct and infarct regions of rat myocardium stained for AT 1 -receptor with indirect immunoflourescence (FITC-labelled). C. is a control section (no primary antibody used). D. AT 1 -receptor staining is evident in both the non-infarcted (on myocytes) and the infarcted region (fibroblasts). localised in the vascular tissue and appears to be present in the endothelial lining of vessels as well (Figure 5b) . The AT 2 -receptor is also localised to myocytes, fibroblasts and myofibroblasts as indicated by the AT 2 -receptor staining (Figure 5d ).
In an attempt to reduce the high, non-specific background fluorescence, the cellular localisation of AT 1 -receptors and AT 2 -receptors was performed using the HRP immunostaining technique. The vascular tissue in the myocardium at the edge of infarct was intensely stained for AT 1 -receptor while the cardiac myocytes and fibrous tissue showed background staining (Figure 6b ). Furthermore, no difference in the intensity of AT 1 -receptor staining was observed when comparing sections of losartan-treated and non-treated groups in myocardial infarcted sections ( Figure  6d ). 
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Differential expression of AT 1 -receptor and cellular markers
Western blot analysis of the expression of AT 1 -receptor from non-infarcted areas of rat heart under various treatments was performed in the context of extracellular matrix remodelling.We used desmin as a marker for myocytes, while vimentin and collagen served as markers for mesenchymal cells. Increased expression of AT 1 -receptor as well as vimentin and collagen I levels in these preparations was observed. The expression of these molecules represents significant changes and remodelling in the non-infarcted region of the heart. Losartan, at the dosage regimen used, did not significantly alter the expression of these proteins (Figure 7) .
Anti-AT 1 -receptor specific antibodies recognised a band at 66 kD in myocardial tissue.To verify AT 1 -receptor identity, the AT 1 -receptor peptide which was used to generate the antibody was added to the anti-AT 1 -receptor specific antibody during incubations, to compete with the AT 1 -receptor binding to the antibody; this resulted in a decrease in the 66 kD band intensity, indicating that it represents AT 1 -receptor (Figure 7a ; lanes e and f).
In MI-operated rat hearts, there was an increase in the intensity of the band (lane c) as compared with sham-operated (lane a). Treatment with losartan (lane d) caused a slight decrease in band intensity as compared with non-treated (lane c).
Alteration in the ECM due to MI was determined by changes in fibroblast proliferation and collagen I deposition.The collagen α-subunit appeared as a 132 kD band (Figure 7b , lane a) whose intensity was increased 2-3 folds in MI rat heart (lane c). Losartan treatment did not alter the expression of collagen I (Figure 7b, lane d) . Similarly vimentin appeared as a 58 kD band (Figure 7c , lane b) that was upregulated after MI but not affected by losartan treatment (Figure 7c, lane d) . From these results, it can be concluded that remodelling of the extracellular matrix at the viable myocardial region involves proliferation of fibroblasts and increased production of collagens to withstand the increase in wall tension.
Angiotensin II binding kinetics
Statistical analysis of the data Statistical analyses and comparisons were made using the student t-test, and the analysis of vari- 
Time-dependent 3 H-Ang II concentration in the effluents in the perfused heart
The following experimental groups were used to assess Ang II binding at the microvascular endothelium and cardiac myocytes;a) sham-operated,losartannon-treated rats, b) MI-operated, losartan-non-treated rats, c) sham-operated and MI-operated, losartan-nontreated and CHAPS-treated, perfused rats, d) shamoperated and MI-operated, losartan-treated rats, and finally e) sham-operated and MI-operated, losartantreated and CHAPS-treated perfused rats. Figure 8 shows a representative plot of the data points of 3 H-Ang II in the effluent vs. time for the sham-operated, losartan untreated rats. The curve is a computer-generated fit to the data points using Eq. 1. The constants a(1), a(2), and a(3) were estimated from the fittings.Values of k n and k -n from Eqs. 4, 5 and 6 as well as k d are calculated and reported in Tables 2 and 3 for all the animal model-treatments.
Discussion
MI is due to sudden coronary occlusion and cessation of blood flow, leading to tissue necrosis, which imposes a serious challenge to the myocardium. This sudden decrease in coronary perfusion stimulates various neuronal and hormonal responses, such as adrenaline and Ang II, resulting in an increase in chronotropic and inotropic properties of the healthy myocardium in an attempt to meet the body's demands. Another important factor is the stress force on the heart wall caused by the intra-cavitary pressure that is now distributed over a smaller myocardial area, leading to stretching of myocytes and ECM, thus resulting in cardiac tissue remodelling.The final outcome of this remodelling process results in increase in myocyte size forming new sarcomeres 19 and alteration in the expression of ECM constituents. 16 The presence of the RAAS in the heart and vessels, as well as the evidence that angiotensin II antagonists decrease cardiac hypertrophy, 22 implicates the involvement of the RAAS in the remodelling process. These facts prompted the present study of the role of the RAAS in this remodelling process, in terms of fibroblast proliferation, collagen deposition, and revascularisation and possible alterations in Ang II binding kinetics with its receptors. Furthermore, an AT 1 -receptor antagonist (losartan) was used to assess its possible protective effects and effects on these parameters.To identify and localise Ang II receptors, immunhistochemistry was used. The data demonstrated that AT 1 -receptor were expressed on myocytes, fibroblasts and vascular tissue (Figures 4, 5 and 6 ). In addition AT 2 -receptor was also detected on myocytes, fibroblasts and endothelial vascular lining (Figures 4, 5 and 6) . This implicates a possible upregulation of the AT 1 -receptor in the vascular tissue in the myocardium of the infarcted heart, although not at the cardiac myocyte and fibrous tissue sites. The AT 2 -receptor did not reflect any specific staining for the upregulation process.
To study the changes in collagen deposition, fibroblast proliferation and AT 1 -receptor expression, Western blotting analysis was used. An increase in the expression of collagen I, vimentin and AT 1 -receptor in MI rat hearts was confirmed ( Figure 7 ). However, losartan did not have any effect on these components as assessed by immunostaining and Western blotting (Figure 7c) .
The binding kinetics of Ang II with its receptors and the possible changes in the affinity of these receptors was addressed by perfusing buffer containing trace amounts of radiolabelled Ang II, hence ruling-out the possibility of ligand-receptor internalisation 23 and consequently the down-regulation of receptors. In addition, it is important to note that evaluating alterations in Ang II binding with its receptors can better be assessed by comparing the residency-time-constant (τ) rather than the dissociation constant (k d ).This is illustrated in the data reported in Tables 2 and 3 , where one can have simultaneous changes in k n and k -n resulting in a non-significant change in the k d value, however a significant change in the τ value is shown [(e.g. 7.08±0.01 vs. 6.97±0.02 (pmol); and 0.48±0.01 vs. 2.33±0.05 (minutes) for the sham-untreated and MIuntreated groups respectively)]. Hence the results reported in Tables 2 and 3 speculate the following: In the sham-operated losartan-untreated perfused rat hearts,Ang II binding with its receptor(s) at the endothelium showed a significant increase compared with the binding at the cardiac myocyte sites in the sham-losartan-untreated-CHAPS-treated group.These results indicate that the AT 1 -receptor expressed at the two sites (τ values, 0.48±0.01 vs. 0.35±0.01 minutes) are not of identical affinities. This may be attributed to the cellular distribution and tissue specificity of the AT 1A -receptor and AT 1B -receptor types of the AT 1 -receptor subtype, owing to differences of expression between the endothelium and cardiomyocyte sites. 24, 25 This is, however, not observed with the sham-operated, losartan-treated vs. sham-operated, losartan-treated-CHAPS-treated groups ( Table 3) , signifying that the Ang II receptor subtype 2 binding does not differ between the two sites (τ values 0.42±0.01 vs. 0.41±0.01 minutes). 26 The reported data between the sham-operated, losartan-untreated and MIlosartan-untreated groups showed that MI resulted in a significant increase in Ang II binding with the capillary endothelium (Table 2) , as observed from the values of the residency time constant (τ values; 0.48±0.01 vs. 2.33±0.05 minutes). Therefore, this suggests that MI may have significantly altered the AT 1 -receptor binding affinity with Ang II at the capillary endothelial cell sites. In addition, comparing the sham-operated, losartan-untreated-CHAPS-treated group and MI-losartan-untreated-CHAPS-treated group, the results showed an increase in residency time constant at the myocyte sites (τ values; 0.35±0.01 vs.0.79±0.06 minutes). Hence, MI probably caused alterations of the AT 1receptor and AT 2 -receptor subtypes both at the capillary endothelium as well as at the myofibre sites. These changes may be due to the upregula-tion 27, 28 of Ang II receptor subtypes 1 and 2 and/or alterations in the receptor structure, and hence alterations in their binding affinity with Ang II. However, the present mathematical model, with its proposed binding constants and specifically the residency time constant, shows independence of the upregulation of receptor number.Therefore,in the sham-operated, losartan-treated group compared with the MIlosartan-treated group, changes in the forward and reversal binding constants and hence in the k d and τ values ( Table 3 ) postulate an increase in Ang II affinity with AT 2 -receptor at the level of coronary endothelium rather than a receptor-upregulatory effect. In addition, the sham-operated, losartan-treated-CHAPS-treated data compared with MI-losartantreated-CHAPS-treated results also indicated changes in the forward and reversal binding constants as well as in the k d and τ values. This signifies that MI induced changes in the receptor structure, thus producing higher affinity in the binding kinetics of Ang II with the AT 2 -receptor subtypes.
The assessment of the comparative binding affinities between the receptor subtypes and Ang II can be observed from the data reported in Tables 2  and 3 . From the sham-operated, losartan-untreated compared with the sham-operated, losartan-treated data it can be noted that Ang II binds with stronger affinity to the AT 1 -receptor than to the AT 2 -receptor (τ values; 0.48±0.01 vs. 0.42±0.01 minutes; p=0.002) at the endothelium site. However, this was not the case at the myocyte site (τ values; 0.35±0.01 vs. 0.41±0.01 minutes; p=0.002). In addition, in the MI-rat hearts, treatment with losartan induced a definitive change in the k n values [0.69±0.02 vs. 0.61±0.02 (M.min) -1 x10 11 ; p=0.02] with an insignificant difference in the τ values (2.33±0.05 vs. 2.40±0.06 minutes; p=0.40). These results suggest that, post-MI, AT 1 -receptor and AT 2receptor, at the coronary vessel endothelium have the same binding affinity with Ang II, indicating that major alterations in the structure of the receptor subtypes may have occurred.The situation with the MI-losartan-untreated-CHAPS-treated compared with the MI-losartan-treated-CHAPS-treated counterpart presented major differences in the binding affinities of Ang II with the AT 1 -receptor and AT 2receptor subtypes at the myocyte site (τ values; 0.79±0.06 vs. 0.50±0.01 minutes; p=0.001). This observed increase in the binding affinity of Ang II with the AT 1 -receptor compared with the AT 2receptor (after losartan treatment) is considered a major putative effect of the peptide in potentiating the pharmacodynamics of hypertrophy.
The mechanisms by which cardiac remodelling occurs as a result of MI can be briefly presented as follows. It is a well-established fact that MI induces pathways that could possibly alter Ang II binding both at the level of the coronary endothelium and the cardiac myocytes.The first explanation is that MI, through its remodelling effect,may induce activation of stretch-operated ionic channels, hence causing influx of Na + and Ca 2+ which then activates various signalling molecules. 29 These events can produce, at different levels, either direct or indirect alterations in the process of Ang II receptor incorporation in the cell membrane, via synthesis and phosphorylation of some transcription factors. 28, 30 The second possible interpretation is that integrins act as mechano-transducers, transmitting mechanical stretching signals caused by MI to microtubules and intermediate filaments that modify allosteric enzymes and generate a cascade of secondary events. 17, 30 These intracellular changes appear to regulate AT 1 -receptor and AT 2receptor gene expression by different mechanisms. The upregulation of AT 1 -receptor is due to increased gene transcription, while AT 2 -receptor upregulation is the result of AT 2 -receptor mRNA stabilisation. 31 We speculate that similar intracellular changes and events are linked to the alteration in AT 1 -receptor and AT 2 -receptor subtype affinity.
In the present experimental model, a one month post MI anomaly can incorporate both types of biochemical and transduced effects as mentioned above, and hence result in alterations of the AT 1receptor and AT 2 -receptor subtypes and consequently of Ang II binding. The results noted above support the fact that MI is possibly inducing, via stretch mechanisms or via induction of ionic channel opening, alterations in the AT 1 -receptor and AT 2receptor, both at the capillary endothelium and the cardiac myocyte levels, irrespective of the probable down-or up-regulation of the AT 1 -receptor or the AT 2 -receptor, 27, 32 and which the proposed physical model accounts for. Therefore, induction of cardiac hypertrophy as a result of MI (Table 1) , could be due to an increase in the binding affinity of Ang II with AT 1 -receptor as the data speculate ( Table 2 ). In addition, one month's treatment with losartan reduced LV hypertrophy, although it did not show post MI, any reversal to the alterations of the morphological remodelling (as illustrated in Figure 7 in the expression of collagen I, vimentin, and desmin). However, losartan did produce an increase in the binding affinity of Ang II with AT 2 -receptor, both at the level of coronary endothelium and the myofibres ( Table 3 ). This increase in binding affinity of Ang II with its AT 2receptor subtype could, in turn, be part of the antigrowth effect of AT 2 -receptor 33 as a result of AT 1receptor subtype receptor blockade by the antagonist, hence inhibiting AT 1 -receptor-dependent growth, 34 and consequently hypertrophy ( Table 1) .
